Acute Brain InjuryCVC-ICPNCT07704528
Effect of Central Venous Catheterization on Brain Pressure in Acute Brain Injury Patients
An observational study of Acute Brain Injury and Traumatic Brain Injury, run by Beijing Tiantan Hospital at 2 sites in China.
Trial summary
Acute brain injury (ABI) is a serious condition that can cause a dangerous increase in pressure inside the skull (called intracranial pressure, or ICP), which can harm the brain. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Brain Injury, Traumatic Brain Injury, Intracerebral Hemorrhage
- How many people
- 120 participants
- Where
- 2 sitesChina
- Study dates
- 1 Mar 2026to 31 Dec 2029
- How long will I take part?
- 28 Days
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients (≥18 years) with acute brain injury (including traumatic brain injury, spontaneous intracerebral hemorrhage, large hemispheric infarction, and aneurysmal subarachnoid hemorrhage) who require invasive intracranial pressure monitoring and are scheduled for clinically indicated percutaneous internal jugular vein catheterization. Patients with ICP >22 mmHg within 48 hours prior to the procedure, contraindications to jugular catheterization (e.g., severe coagulopathy, local neck pathology, bilateral catheters already in place), or who are pregnant/breastfeeding are excluded. The study population is recruited from two ICUs in China (Beijing Tiantan Hospital and Guiyang Second People's Hospital).
Who may be able to join
- Age ≥ 18 years
- Admitted to the ICU with acute brain injury (including traumatic brain injury, spontaneous intracerebral hemorrhage, large hemispheric infarction, or aneurysmal subarachnoid hemorrhage) and ICU stay ≥ 24 hours
- Invasive intracranial pressure (ICP) monitoring in place as part of clinical care
- Scheduled to undergo percutaneous internal jugular vein catheterization (central venous catheter) as determined by the treating physician
- Written informed consent obtained from the patient or legally authorized representative
Who cannot join
- Informed consent not obtained
- Intracranial pressure (ICP) > 22 mmHg within the past 48 hours
- Any contraindication to internal jugular catheterization exists (severe coagulopathy with INR > 1.5 or platelets < 50×10⁹/L; neck infection, tumor, prior surgery or anatomical abnormality on either side; or bilateral jugular veins already catheterized)
- Pregnancy or breastfeeding
Trial locations and contacts
2 sites in 1 country.
China2 sites
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, 100070
The Second People's Hospital of Guiyang
Guiyang, Guizhou, 550081
About this study
Official title: Effect of Percutaneous Internal Jugular Vein Catheterization on Intracranial Pressure in Patients With Acute Brain Injury
Acute brain injury (ABI) is a serious condition that can cause a dangerous increase in pressure inside the skull (called intracranial pressure, or ICP), which can harm the brain. Patients with ABI often need a central venous catheter (CVC) - a small, flexible tube placed into a large neck vein - to receive medications, fluids, and to monitor their circulation. However, placing this catheter might temporarily affect brain pressure, either because of the patient's head position during the procedure or the procedure itself. The effect size and duration are not yet known.
The purpose of this observational study is to understand how placing a CVC in the neck (internal jugular vein) affects brain pressure in patients with acute brain injury. The study will closely monitor changes in brain pressure, blood flow, and oxygen levels in the brain during and immediately after the procedure. The study will also examine whether the brain's ability to regulate its own blood flow (called cerebral autoregulation) influences these changes.
Read more
This prospective, observational study will enroll approximately 100-120 adult patients with ABI who are in the Intensive Care Unit (ICU) and need a CVC as part of their regular medical care. The study will be conducted in two large hospitals in China. There is no experimental treatment or intervention; only observation and data recording during the standard medical procedure will be performed.
The main goal is to measure how brain pressure changes during CVC insertion. The study will also look at how long any changes last and whether the brain's blood flow regulation is affected. The results will help doctors better understand the risks of this common procedure and guide safer management of ABI patients in the ICU.
Read the detailed description
Study Design This is a prospective, multicenter, observational cohort study. The study will be conducted in two intensive care units (ICUs) in China: Beijing Tiantan Hospital (primary center) and Guiyang Second People's Hospital (collaborating center). No experimental intervention is administered; all procedures are part of routine clinical care.
Population and Enrollment A total of 100-120 adult patients (≥18 years) with acute brain injury who require invasive intracranial pressure (ICP) monitoring and are scheduled for percutaneous internal jugular vein catheterization (central venous catheter, CVC) will be enrolled. Enrollment is expected to take 24 months (from March 2026 to February 2028). (Specific etiologies are not listed here as they are detailed in the Eligibility Criteria section.)
Exposure The exposure of interest is the performance of percutaneous internal jugular vein catheterization using the Seldinger technique. The procedure is performed by the patient's primary medical team according to institutional standards, with the patient lying supine, head turned to the contralateral side, and a shoulder roll placed if needed. Ultrasound guidance may be used at the operator's discretion.
Multimodal Monitoring
All enrolled patients already have an ICP monitor in place as part of clinical management (Codman microtransducer or external ventricular drain). Additionally, the following neuromonitoring parameters will be recorded continuously before, during, and after the CVC procedure:
Intracranial pressure (ICP) and derived cerebral perfusion pressure (CPP = MAP - ICP)
Cerebral autoregulation: assessed by pressure reactivity index (PRx) in Beijing Tiantan Hospital, or by transient hyperemic response test (THRT) using transcranial Doppler in Guiyang Second People's Hospital
Regional cerebral oxygen saturation (rSO₂): using near-infrared spectroscopy (EGOS-600A)
Bispectral index (BIS) as an indicator of sedation level
End-tidal CO₂ (EtCO₂) and ventilator parameters (for mechanically ventilated patients)
Hemodynamics: heart rate, systolic/diastolic/mean arterial pressure
All data are collected from existing clinical monitors and recorded at baseline, during catheterization, and up to 30 minutes after the procedure.
Data Collection and Quality Control Data will be collected by trained ICU physicians using standardized case report forms. Two independent data entries will be performed, with discrepancies resolved by consensus with a senior investigator. All personal identifiers will be removed, and a unique study ID will be assigned to each participant. Data will be stored in a password-protected database.
Statistical Analysis Continuous variables will be compared using paired t-test or repeated-measures ANOVA (for normally distributed data) or Wilcoxon signed-rank test / Friedman test (for non-normal data). The relationship between ICP changes and patient/procedural factors will be analyzed using linear mixed-effects models or generalized estimating equations. A subgroup analysis will compare patients with intact versus impaired cerebral autoregulation. All tests will be two-sided with α = 0.05. Sample size was calculated to detect a clinically relevant change in the primary ICP parameter, with 80% power and accounting for a 15% dropout rate; the target enrollment is 100-120 patients to allow for subgroup analyses.
Ethics and Consent The study protocol has been approved by the Institutional Review Board of Beijing Tiantan Hospital, Capital Medical University (approval number: KY 2021-006-02). Written informed consent will be obtained from each patient or their legally authorized representative prior to enrollment. The study is registered at ClinicalTrials.gov (NCT number to be assigned). All procedures are conducted in accordance with the Declaration of Helsinki.
- Conditions
- Acute Brain Injury, Traumatic Brain Injury, Intracerebral Hemorrhage, Aneurysmal Subarachnoid Hemorrhage (aSAH), Intracranial Hypertension, Central Venous Catheter
- Keywords
- Acute brain injury, Intracranial hypertension, Central Venous Catheter
- Medical subject headings
- Brain Injuries, Brain Injuries, Traumatic, Cerebral Hemorrhage, Subarachnoid Hemorrhage, Intracranial Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| ABI patients undergoing internal jugular vein catheterization | Adult patients (≥18 years) with acute brain injury (including traumatic brain injury, intracerebral hemorrhage, large hemispheric infarction, and aneurysmal subarachnoid hemorrhage) who require invasive intracranial pressure monitoring and are scheduled to undergo percutaneous internal jugular vein catheterization (central venous catheter) as part of routine clinical care. No experimental intervention is administered; the exposure of interest is the catheterization procedure itself. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Intracranial Pressure (ICP)
Change in ICP (mmHg) from baseline during and after percutaneous internal jugular vein catheterization. A clinically significant ICP elevation is defined as ≥22 mmHg sustained for more than 5 minutes.
Measured: Baseline (immediately pre-procedure) to 30 minutes after catheter placement.
Secondary outcomes (6)
Change in Cerebral Perfusion Pressure (CPP)
Change in Cerebral Perfusion Pressure (CPP) in mmHg.
Measured: Measured from baseline to 30 minutes post-procedure.
Change in Regional Cerebral Oxygen Saturation (rSO₂)
Change in Regional Cerebral Oxygen Saturation (rSO₂) in percent (%).
Measured: Baseline to 30 minutes after catheter placement.
Change in Bispectral Index (BIS)
Change in Bispectral Index (BIS). BIS is a dimensionless scale ranging from 0 to 100. Measured from baseline to 30 minutes post-procedure.
Measured: Baseline to 30 minutes after catheter placement.
Change in Cerebral Autoregulation Index
Change in Cerebral Autoregulation Index assessed by the Pressure Reactivity Index (PRx) at Beijing Tiantan Hospital. PRx is a dimensionless correlation index derived from ICP and arterial blood pressure, and will be calculated by integrating arterial blood pressure data using NEUSTRO software (Shanghai Haoju Medical Technology Co., Ltd.). At Guiyang Second People's Hospital, due to the lack of corresponding software, the transient hyperemic response test (THRT), as measured by transcranial Doppler (TCD), will be used to assess cerebral autoregulation.
Measured: Measured from baseline to 30 minutes post-procedure.
Incidence of Delayed Cerebral Ischemia (DCI)
Incidence of Delayed Cerebral Ischemia (DCI) during hospital stay. DCI is defined as a new focal neurological deficit or a decline in Glasgow Coma Scale not attributable to other causes, with radiological or other confirmatory evidence. Reported as the number of participants with events (proportion).
Measured: From enrollment to hospital discharge, assessed up to 30 days.
In-hospital all-cause mortality
In-hospital all-cause mortality will be reported as the number of deaths during the index hospitalization (proportion).
Measured: From enrollment to hospital discharge, assessed up to 30 days.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jul 2026
- Study start1 Mar 2026
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Brain InjuryStudies of the same condition, open and under way.
- More trials run by Beijing Tiantan HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 120 participants (estimated)
- Target duration
- 28 Days
Sponsor and investigators
- Lead sponsor
- Beijing Tiantan Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jianfang Zhou, Beijing Tiantan Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07704528
- Sponsor's protocol ID
- HX-B-2026001
- Acronym
- CVC-ICP
- Status last verified
- Jul 2026
- First submitted
- 15 Jun 2026
- Last updated
- 15 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Percutaneous Internal Jugular Vein Catheterization on Intracranial Pressure in Patients With Acute Brain Injury
- ClinicalTrials.gov ID
- NCT07704528
- Acronym / sponsor ID
- CVC-ICP / HX-B-2026001
- Conditions
- Acute Brain Injury, Traumatic Brain Injury, Intracerebral Hemorrhage, Aneurysmal Subarachnoid Hemorrhage (aSAH), Intracranial Hypertension, Central Venous Catheter
- Keywords
- Acute brain injury, Intracranial hypertension, Central Venous Catheter
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Beijing Tiantan HospitalUniversity, hospital or other
- Study start
- 1 Mar 2026 (actual)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 15 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Acute brain injury (ABI) is a serious condition that can cause a dangerous increase in pressure inside the skull (called intracranial pressure, or ICP), which can harm the brain. Patients with ABI often need a central venous catheter (CVC) - a small, flexible tube placed into a large neck vein - to receive medications, fluids, and to monitor their circulation. However, placing this catheter might temporarily affect brain pressure, either because of the patient's head position during the procedure or the procedure itself. The effect size and duration are not yet known.
The purpose of this observational study is to understand how placing a CVC in the neck (internal jugular vein) affects brain pressure in patients with acute brain injury. The study will closely monitor changes in brain pressure, blood flow, and oxygen levels in the brain during and immediately after the procedure. The study will also examine whether the brain's ability to regulate its own blood flow (called cerebral autoregulation) influences these changes.
This prospective, observational study will enroll approximately 100-120 adult patients with ABI who are in the Intensive Care Unit (ICU) and need a CVC as part of their regular medical care. The study will be conducted in two large hospitals in China. There is no experimental treatment or intervention; only observation and data recording during the standard medical procedure will be performed.
The main goal is to measure how brain pressure changes during CVC insertion. The study will also look at how long any changes last and whether the brain's blood flow regulation is affected. The results will help doctors better understand the risks of this common procedure and guide safer management of ABI patients in the ICU.
Detailed description
Study Design This is a prospective, multicenter, observational cohort study. The study will be conducted in two intensive care units (ICUs) in China: Beijing Tiantan Hospital (primary center) and Guiyang Second People's Hospital (collaborating center). No experimental intervention is administered; all procedures are part of routine clinical care.
Population and Enrollment A total of 100-120 adult patients (≥18 years) with acute brain injury who require invasive intracranial pressure (ICP) monitoring and are scheduled for percutaneous internal jugular vein catheterization (central venous catheter, CVC) will be enrolled. Enrollment is expected to take 24 months (from March 2026 to February 2028). (Specific etiologies are not listed here as they are detailed in the Eligibility Criteria section.)
Exposure The exposure of interest is the performance of percutaneous internal jugular vein catheterization using the Seldinger technique. The procedure is performed by the patient's primary medical team according to institutional standards, with the patient lying supine, head turned to the contralateral side, and a shoulder roll placed if needed. Ultrasound guidance may be used at the operator's discretion.
Multimodal Monitoring
All enrolled patients already have an ICP monitor in place as part of clinical management (Codman microtransducer or external ventricular drain). Additionally, the following neuromonitoring parameters will be recorded continuously before, during, and after the CVC procedure:
Intracranial pressure (ICP) and derived cerebral perfusion pressure (CPP = MAP - ICP)
Cerebral autoregulation: assessed by pressure reactivity index (PRx) in Beijing Tiantan Hospital, or by transient hyperemic response test (THRT) using transcranial Doppler in Guiyang Second People's Hospital
Regional cerebral oxygen saturation (rSO₂): using near-infrared spectroscopy (EGOS-600A)
Bispectral index (BIS) as an indicator of sedation level
End-tidal CO₂ (EtCO₂) and ventilator parameters (for mechanically ventilated patients)
Hemodynamics: heart rate, systolic/diastolic/mean arterial pressure
All data are collected from existing clinical monitors and recorded at baseline, during catheterization, and up to 30 minutes after the procedure.
Data Collection and Quality Control Data will be collected by trained ICU physicians using standardized case report forms. Two independent data entries will be performed, with discrepancies resolved by consensus with a senior investigator. All personal identifiers will be removed, and a unique study ID will be assigned to each participant. Data will be stored in a password-protected database.
Statistical Analysis Continuous variables will be compared using paired t-test or repeated-measures ANOVA (for normally distributed data) or Wilcoxon signed-rank test / Friedman test (for non-normal data). The relationship between ICP changes and patient/procedural factors will be analyzed using linear mixed-effects models or generalized estimating equations. A subgroup analysis will compare patients with intact versus impaired cerebral autoregulation. All tests will be two-sided with α = 0.05. Sample size was calculated to detect a clinically relevant change in the primary ICP parameter, with 80% power and accounting for a 15% dropout rate; the target enrollment is 100-120 patients to allow for subgroup analyses.
Ethics and Consent The study protocol has been approved by the Institutional Review Board of Beijing Tiantan Hospital, Capital Medical University (approval number: KY 2021-006-02). Written informed consent will be obtained from each patient or their legally authorized representative prior to enrollment. The study is registered at ClinicalTrials.gov (NCT number to be assigned). All procedures are conducted in accordance with the Declaration of Helsinki.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 28 Days
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| ABI patients undergoing internal jugular vein catheterization | – | –Adult patients (≥18 years) with acute brain injury (including traumatic brain injury, intracerebral hemorrhage, large hemispheric infarction, and aneurysmal subarachnoid hemorrhage) who require invasive intracranial pressure monitoring and are scheduled to undergo percutaneous internal jugular vein catheterization (central venous catheter) as part of routine clinical care. No experimental intervention is administered; the exposure of interest is the catheterization procedure itself. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients (≥18 years) with acute brain injury (including traumatic brain injury, spontaneous intracerebral hemorrhage, large hemispheric infarction, and aneurysmal subarachnoid hemorrhage) who require invasive intracranial pressure monitoring and are scheduled for clinically indicated percutaneous internal jugular vein catheterization. Patients with ICP >22 mmHg within 48 hours prior to the procedure, contraindications to jugular catheterization (e.g., severe coagulopathy, local neck pathology, bilateral catheters already in place), or who are pregnant/breastfeeding are excluded. The study population is recruited from two ICUs in China (Beijing Tiantan Hospital and Guiyang Second People's Hospital).
Key inclusion criteria (5 listed)
- Age ≥ 18 years
- Admitted to the ICU with acute brain injury (including traumatic brain injury, spontaneous intracerebral hemorrhage, large hemispheric infarction, or aneurysmal subarachnoid hemorrhage) and ICU stay ≥ 24 hours
- Invasive intracranial pressure (ICP) monitoring in place as part of clinical care
- Scheduled to undergo percutaneous internal jugular vein catheterization (central venous catheter) as determined by the treating physician
- Written informed consent obtained from the patient or legally authorized representative
Key exclusion criteria (4 listed)
- Informed consent not obtained
- Intracranial pressure (ICP) > 22 mmHg within the past 48 hours
- Any contraindication to internal jugular catheterization exists (severe coagulopathy with INR > 1.5 or platelets < 50×10⁹/L; neck infection, tumor, prior surgery or anatomical abnormality on either side; or bilateral jugular veins already catheterized)
- Pregnancy or breastfeeding
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Change in Intracranial Pressure (ICP)
Time frame: Baseline (immediately pre-procedure) to 30 minutes after catheter placement.
Change in ICP (mmHg) from baseline during and after percutaneous internal jugular vein catheterization. A clinically significant ICP elevation is defined as ≥22 mmHg sustained for more than 5 minutes.
6 secondary outcomes
Change in Cerebral Perfusion Pressure (CPP)
Time frame: Measured from baseline to 30 minutes post-procedure.
Change in Regional Cerebral Oxygen Saturation (rSO₂)
Time frame: Baseline to 30 minutes after catheter placement.
Change in Bispectral Index (BIS)
Time frame: Baseline to 30 minutes after catheter placement.
Change in Cerebral Autoregulation Index
Time frame: Measured from baseline to 30 minutes post-procedure.
Incidence of Delayed Cerebral Ischemia (DCI)
Time frame: From enrollment to hospital discharge, assessed up to 30 days.
In-hospital all-cause mortality
Time frame: From enrollment to hospital discharge, assessed up to 30 days.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Acute Brain Injury
RecruitingObservational study
Sleep to Predict Recovery In Unconscious Patients With Acute Brain Injury
Traumatic Brain Injury (TBI) Patients, Intracerebral Hemorrhage (ICH)
Recruiting
The Coma Family Program (COMA-F): A Resilience Program for Caregivers of Patients With Severe Acute Brain Injury
Caregiver Distress, Emotional Distress
Recruiting
Rapid Local Ischemic Postconditioning on Stroke After Thrombectomy
Acute Ischemic Stroke
Enrolling by invitation
Fareon Open Label Device Clinical Trial
Cognitive Dysfunction, Acquired Brain Injury
Not yet recruiting
Supplementary Neuromuscular Rehabilitation During Acute Concussion Recovery
Concussion (Diagnosis), Gait Abnormality
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Brain Injury and Traumatic Brain Injury, run by Beijing Tiantan Hospital at 2 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 15 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Intracranial Pressure (ICP) (time frame: Baseline (immediately pre-procedure) to 30 minutes after catheter placement.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jul 2026.